Del Paggio J C, Nanji S, Wei X, MacDonald P H, Booth C M
Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute.
Departments of Oncology; Surgery.
Curr Oncol. 2017 Feb;24(1):e35-e43. doi: 10.3747/co.24.3210. Epub 2017 Feb 27.
Guidelines recommend that 12 or more lymph nodes (lns) be evaluated during surgical resection of colon cancer. Here, we report ln yield and its association with survival in routine practice.
Electronic records of treatment were linked to the population-based Ontario Cancer Registry to identify all patients with colon cancer treated during 2002-2008. The study population ( = 5508) included a 25% random sample of patients with stage ii or iii disease. Modified Poisson regression was used to identify factors associated with ln yield; Cox models were used to explore the association between ln yield and overall (os) and cancer-specific survival (css).
During 2002-2008, median ln yield increased to 17 from 11 nodes ( < 0.001), and the proportion of patients with 12 or more nodes evaluated increased to 86% from 45% ( < 0.001). Lymph node positivity did not change over time (to 53% from 54%, = 0.357). Greater ln yield was associated with younger age ( < 0.001), less comorbidity ( = 0.004), higher socioeconomic status ( = 0.001), right-sided tumours ( < 0.001), and higher hospital volume ( < 0.001). In adjusted analyses, a ln yield of less than 12 nodes was associated with inferior os and css for stages ii and iii disease [stage ii os hazard ratio (hr): 1.36; 95% confidence interval (ci): 1.19 to 1.56; stage ii css hr: 1.52; 95% ci: 1.26 to 1.83; and stage iii os hr: 1.45; 95% ci: 1.30 to 1.61; stage iii css hr: 1.54; 95% ci: 1.36 to 1.75].
Despite a temporal increase in ln yield, the proportion of cases with ln positivity has not changed. Lymph node yield is associated with survival in patients with stages ii and iii colon cancer. The association between ln yield and survival is unlikely to be a result of stage migration.
指南建议在结肠癌手术切除过程中评估12个或更多的淋巴结。在此,我们报告了常规实践中淋巴结的获取数量及其与生存的关系。
将治疗的电子记录与基于人群的安大略癌症登记处相链接,以识别2002年至2008年期间接受治疗的所有结肠癌患者。研究人群(n = 5508)包括ii期或iii期疾病患者的25%随机样本。采用修正泊松回归来识别与淋巴结获取数量相关的因素;使用Cox模型来探讨淋巴结获取数量与总生存(OS)和癌症特异性生存(CSS)之间的关系。
在2002年至2008年期间,淋巴结获取数量的中位数从11个增加到17个(P < 0.001),评估12个或更多淋巴结的患者比例从45%增加到86%(P < 0.001)。淋巴结阳性率未随时间变化(从54%降至53%,P = 0.357)。更高的淋巴结获取数量与更年轻的年龄(P < 0.001)、更少的合并症(P = 0.004)、更高的社会经济地位(P = 0.001)、右侧肿瘤(P < 0.001)以及更高的医院容量(P < 0.001)相关。在多因素分析中,对于ii期和iii期疾病,获取少于12个淋巴结与较差的OS和CSS相关[ii期OS风险比(HR):1.36;95%置信区间(CI):1.19至1.56;ii期CSS HR:1.52;95%CI:1.26至1.83;iii期OS HR:1.45;95%CI:1.30至1.61;iii期CSS HR:1.54;95%CI:1.36至1.75]。
尽管淋巴结获取数量随时间增加,但淋巴结阳性病例的比例并未改变。淋巴结获取数量与ii期和iii期结肠癌患者的生存相关。淋巴结获取数量与生存之间的关联不太可能是分期迁移的结果。